Ionis' Zanvastro approval tests whether antisense can fund itself right after the TTR miss

On Sept. 3, 2026, the FDA approved Ionis’ ZANVASTRO (zilganersen) injection as the first FDA-approved treatment for Alexander disease. The FDA positions the drug as a targeted antisense therapy designed to reduce production of abnormal GFAP and slow the protein buildup that drives disease biology. It gives Ionis a solo U.S. commercialization test of CNS antisense at quarterly, intrathecal scale, with the label covering pediatric through adult patients.

For an ultra-rare disease like Alexander disease, the commercialization bottleneck is usually not “market size,” but whether patients can reach treatment fast enough, repeatedly enough, and under enough payer coverage to sustain demand. The FDA approval itself is only the first gate. Ionis’ own announcement emphasizes a structured patient support layer (education, insurance navigation, and affordability resources), which is designed to reduce the practical time lag between prescription and coverage decisions.

This approval matters for the antisense platform in a very specific way: it is not a generic “RNA wins again” headline. It is a CNS, protein-buildup disease mechanism (GFAP) with an intrathecal administration requirement, which is exactly where delivery, safety monitoring, and payer justification are hardest. Separately, Ionis’ licensing deal around zilganersen is split by geography: Ionis retains U.S. commercialization responsibility, while Recordati (outside the U.S.) leads development/commercialization. That split can help investors isolate whether antisense execution risk is execution-by-region (partners) or execution-by-company (U.S. launch).

The Ionis release on the approval is paired with a June 25, 2026 licensing agreement that clarifies how responsibilities are divided. Ionis said Recordati obtained exclusive rights to develop and commercialize zilganersen in all countries outside the U.S. In return, Ionis received a $30 million upfront payment, plus eligibility for milestone payments and tiered royalties described up to the mid-20% range on annual net sales. This matters because it sets the experiment: can Ionis turn U.S. execution into cash generation while still monetizing ex-U.S. royalties, rather than depending on a partner to do all the commercialization heavy lifting.

Ionis is still a cash-burn story. Using annual financials, FY 2025 shows $944.0M revenue and a net loss of $381.4M, with operating cash flow of about -$268.6M and free cash flow of about -$320.0M. That means investors should treat this approval as a funding-ceiling changer, not a near-term earnings inflection. If ZANVASTRO becomes reimbursed and repeat-dosed reliably in the U.S., it can support valuation via (1) expectation of future commercial revenue, and (2) reduced perceived probability that Ionis must dilute shareholders to keep funding CNS antisense development.

In rare CNS therapeutics delivered intrathecally, demand formation has a long tail: it starts with clinicians who can administer therapy safely, then with coverage determinations, then with scheduling. If Ionis’ support program reduces coverage friction, approvals should translate into initial treatment uptake; the second inflection is persistence—patients returning every ~12 weeks for ongoing dosing. If persistence is strong, payer confidence tends to improve over time, which can reduce re-authorization friction and lift net realizations.